CN114401985A - 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体 - Google Patents

用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体 Download PDF

Info

Publication number
CN114401985A
CN114401985A CN202080063811.XA CN202080063811A CN114401985A CN 114401985 A CN114401985 A CN 114401985A CN 202080063811 A CN202080063811 A CN 202080063811A CN 114401985 A CN114401985 A CN 114401985A
Authority
CN
China
Prior art keywords
pro
val
polypeptide
ser
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080063811.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·Z·曹
R·施皮里格
A·祖尔切尔
A·柏兹摩瑞丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
Original Assignee
CSL Behring Recombinant Facility AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Recombinant Facility AG filed Critical CSL Behring Recombinant Facility AG
Publication of CN114401985A publication Critical patent/CN114401985A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080063811.XA 2019-09-13 2020-09-11 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体 Pending CN114401985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197287.6 2019-09-13
EP19197287 2019-09-13
PCT/EP2020/075432 WO2021048330A1 (en) 2019-09-13 2020-09-11 Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders

Publications (1)

Publication Number Publication Date
CN114401985A true CN114401985A (zh) 2022-04-26

Family

ID=68084577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080063811.XA Pending CN114401985A (zh) 2019-09-13 2020-09-11 用于治疗免疫复合物介导的肾病症的重组IgG Fc多聚体

Country Status (9)

Country Link
US (1) US20220332847A1 (https=)
EP (1) EP4028415A1 (https=)
JP (2) JP7734652B2 (https=)
KR (1) KR20220062084A (https=)
CN (1) CN114401985A (https=)
AU (1) AU2020344164A1 (https=)
BR (1) BR112022003713A2 (https=)
CA (1) CA3150680A1 (https=)
WO (1) WO2021048330A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052654A (zh) * 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
WO2018129255A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
CN108602857A (zh) * 2016-01-27 2018-09-28 瑞士杰特贝林生物制品重组设备股份公司 重组IgG Fc多聚体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL2185589T3 (pl) 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
TWI542597B (zh) 2010-07-28 2016-07-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
WO2013112986A1 (en) 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
CA2939201A1 (en) 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
KR20250053203A (ko) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
US20210095006A1 (en) * 2017-12-14 2021-04-01 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF NEUROMYELITIS OPTICA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101052654A (zh) * 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
CN108602857A (zh) * 2016-01-27 2018-09-28 瑞士杰特贝林生物制品重组设备股份公司 重组IgG Fc多聚体
WO2018129255A1 (en) * 2017-01-06 2018-07-12 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs

Also Published As

Publication number Publication date
JP7734652B2 (ja) 2025-09-05
US20220332847A1 (en) 2022-10-20
WO2021048330A1 (en) 2021-03-18
AU2020344164A1 (en) 2022-04-14
JP2022547692A (ja) 2022-11-15
BR112022003713A2 (pt) 2022-08-09
CA3150680A1 (en) 2021-03-18
JP2025124714A (ja) 2025-08-26
KR20220062084A (ko) 2022-05-13
EP4028415A1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
JP7593745B2 (ja) エンジニアリングされたＦｃ構築物に関連する組成物および方法
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
CN110573532B (zh) TGF-β 受体胞外域融合分子及其用途
JP7045333B6 (ja) 操作されたＦｃコンストラクトに関する組成物及び方法
ES2758480T3 (es) Proteína de unión a RGMa y uso de la misma
CN113271972B (zh) 用于替代IVIG的多聚体杂交Fc蛋白
JP7097293B2 (ja) ヒトＦｃ受容体に結合する融合タンパク質
KR102884943B1 (ko) 개선된 항-flt3 항원 결합 단백질
CN107207623B (zh) Fc融合高亲和力IgE受体α链
EP4242232A1 (en) Bispecific antibody and use thereof
EA035269B1 (ru) АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР
KR20190099333A (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
WO2018032639A1 (zh) 活化的人凝血因子vii融合蛋白及其制备方法与用途
KR20230129423A (ko) 면역 세포 기능 조절을 위한 항원 결합 분자와 돌연변이인터루킨-10 폴리펩티드의 융합
JP2017508446A (ja) 二機能性融合タンパク質及びその製造方法並びに使用
WO2024046301A1 (zh) 包含taci多肽的融合蛋白及其用途
JP7734652B2 (ja) 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体
JP7674837B2 (ja) Ａｐｊ抗体及びｅｌａｂｅｌａとのその融合タンパク質並びにその医薬組成物及び用途
US12122813B2 (en) Fusion protein comprising an antigen binding domain and a cytokine trimer domain
TWI858383B (zh) 一種ｃｄｃ平臺抗體
TW202608922A (zh) 特異性結合ｂｄｃａ－２的單克隆抗體或其抗原結合片段及其用途
CN121548586A (zh) 免疫治疗蛋白
HK40092774A (zh) 使用激活素受体ii型变体的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination